
Gimv et al. invest €5.5m in pharma company Multiplicom
Gimv and regional Belgian players have invested €5.5m in Antwerp-based biotechnology company Multiplicom NV.
Other investors included Flemish investment company PMV, RMM (Rudi Marien), Belgian inter-university venture capital fund Qbic, and Flanders-based life sciences research institute VIB.
Gimv, VIB and Biotech Fonds Flanderen, which is managed my Gimv, invested €2m in Multiplicom in April 2011.
Company
Multiplicom is a Belgian biotechnology company that produces molecular diagnostic kits for laboratory testing of personalised medicine. It sells kits for bowel cancer, heart failure and cystic fibrosis, as well as kidney and muscle disease.
The company was founded in 2010, when it span out of the University of Antwerp and VIB.
People
Health and care associate Christophe van Vaeck led the investment for Gimv. Life sciences investment manager Bram Vanparys represented PMV, while managing partner Marc Zabeau represented Qbic. Dirk Pollet is CEO of Multiplicom.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater